Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

The Fallout from the Fatal Drug Study in France

By Drug Discovery Trends Editor | January 21, 2016

The aftermath of a catastrophic clinical trial in France has raised concerns regarding the lack of data shared about the incident.  

Last week, the French Health Ministry reported that six patients taking part in a Phase 1 clinical trial administered by Portuguese drug manufacturer Bial for an alleged painkiller containing cannabinoids were rushed to a local hospital after experiencing adverse events. The situation deteriorated over the weekend when one of the patients who was in a coma passed away while the others remained hospitalized, but stable.

More information arrived later, shedding insight into what happened.

First, investigators determined that the drug in question didn’t contain cannabis or any substance linked to it. A report in Nature indicated the treatment was a fatty acid amide hydrolase (FAAH) inhibitor, which is an “enzyme produced in the brain and elsewhere in the body that breaks down neurotransmitters known as endocannabinoids.”

Nature adds that other companies have developed FAAH inhibitors to test their painkilling capabilities. However, clinical research has shown these compounds to be ineffective for this purpose, although they proved to be safe.

Bial wasn’t immediately forthcoming about which molecule was used in these trials.

STAT writes two scientists identified the compound as BIA 10-2474, despite it not being available in the databases where clinical trials are usually registered. A Bial spokeswoman confirmed to STAT this was indeed the drug, although she declined to elaborate on whether more information would be released.

READ MORE: Drugmakers Propose New Plan for Fighting Superbugs

All of this emphasizes why scientists are calling for greater transparency when it comes to clinical trials.

Another STAT report explains Phase 1 trial results “are not required to be publicly released to data repositories in Europe or the United States” because this specific set of trials are exempt from a disclosure law that requires the public reporting of late-stage clinical tests.

Phase 1 tests tend to be small-scale in order to determine the safety of a certain drug. Early-stage results can be voluntarily submitted, but the law necessitates submitting information from later-stage trials since this part of the process involves closely analyzing a drug’s safety and efficacy profile.

A study published in the journal BMJ Open in November 2015 notes that full disclosure of the entire trial process could ultimately protect human subjects from participating in failed experiments. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50